Where EGFR-mutant lung cancer treatment is heading
EGFR-mutant lung cancer · Updated Nov 15, 2026
About 1 in 7 non-small cell lung cancers in the US, and about 4 in 10 in East Asia, carry an EGFR mutation, often in people who never smoked. Daily osimertinib pills are the backbone of treatment, and two stronger first-line options now extend survival: adding chemotherapy (FLAURA2) or switching to amivantamab plus lazertinib (MARIPOSA). Research is focused on what to do when osimertinib stops working, with drug-carrying antibodies (antibody-drug conjugates) leading, and on treating earlier-stage disease around surgery and radiation.
- 247studies open or running
- 54phase 3 trials
- 1,214papers published this year
- 4NIH-funded projects
-
Now
Nov 2026
Two stronger first treatmentsHappened 47.5 months median survival
Osimertinib plus chemo (47.5 vs 37.6 months median survival) and amivantamab plus lazertinib (60% vs 51% alive at 3 years) both beat osimertinib alone.
47.5: months median survival with osimertinib plus chemo, vs 37.6 alone.
Drug-carrying antibodies after resistanceHappened 8.3 months without progression
Sac-TMT and a HER3 antibody-drug conjugate both delayed growth for about 8 months vs 4 to 5 with chemo in Chinese phase 3 trials.
8.3: months without progression with sac-TMT, vs 4.3 with chemotherapy.
Osimertinib earlier in the diseaseHappened 39.1 months without progression
After chemoradiation it delayed progression for 39.1 vs 5.6 months; before surgery it left little cancer behind in 26% vs 2%.
39.1: months without progression after chemoradiation, vs 5.6 with placebo.
-
6 months
by May 2027
Dato-DXd after osimertinibLikely
AstraZeneca's TROPION-Lung15 (768 people) tests Dato-DXd, alone or with osimertinib, against chemotherapy after osimertinib; due January 2027.
A first pill trial for exon 20Possible
ArriVent's FURVENT (398 people) compares firmonertinib with chemotherapy for exon 20 insertions; its main analysis was due October 2026.
-
12 months
by Nov 2027
Sac-TMT tested worldwidePossible 8.3 months without progression (China)
Merck's global trial (556 people) compares sac-TMT with chemotherapy in previously treated disease; due May 2027.
8.3: months without progression with sac-TMT in China, vs 4.3 with chemotherapy.
Osimertinib for very early cancerPossible
AstraZeneca's ADAURA2 (390 people) tests osimertinib after surgery for stage IA2 to IB tumors; due August 2027.
Zipalertinib plus chemo firstPossible 35.2% tumors shrank (later line)
Taiho's REZILIENT3 (285 people) adds zipalertinib to first-line chemotherapy for exon 20 insertions; due May 2027.
35.2%: of exon 20 tumors shrank on zipalertinib alone.
-
3 years
by late 2029
An antibody-drug conjugate in first linePossible
TROPION-Lung14 (582 people) adds Dato-DXd to first-line osimertinib; due March 2028. A win could change first treatment again.
Iza-bren against chemotherapyPossible 47.4% tumors shrank (early trials)
Bristol Myers Squibb's IZABRIGHT-Lung01 (661 people) is due December 2028.
47.4%: of tumors shrank in early trials.
-
5 years
by late 2031
Pills after surgery for rarer mutationsPossible
Zipalertinib (REZILIENT4) and sunvozertinib trials test post-surgery treatment for exon 20 and other uncommon mutations; due 2029.
Personalized first-line choicesLong shot 60% alive at 3 years
With several first-line combinations available, trials aim to match treatment to risk, for example by mutation type and brain metastases.
60%: alive at 3 years with amivantamab plus lazertinib, vs 51%.
The research paths
Antibody-drug conjugates
8.3 months without progressionDetails and 6 trialsHide
Antibodies that carry chemotherapy straight into cancer cells, aimed at TROP2, HER3, EGFR-HER3 or c-Met. Several have beaten chemotherapy after resistance and are moving earlier.
WatchTROPION-Lung15; TROPION-Lung14; IZABRIGHT-Lung01.
- OptiTROP-Lung04 trial (sac-TMT)
- HERON-Lung01 trial (HER3 antibody-drug conjugate)
- Iza-bren early trials
- Dato-DXd with or without osimertinib (TROPION-Lung15)AstraZeneca · 768 people · fully enrolled Jan 2027
- Osimertinib with or without Dato-DXd, first line (TROPION-Lung14)AstraZeneca · 582 people · enrolling Mar 2028
- Sac-TMT vs chemotherapy after EGFR pillsMerck · 550 people · fully enrolled Aug 2028
- Sac-TMT vs chemotherapy, later linesMerck · 556 people · fully enrolled May 2027
- Iza-bren vs chemotherapy (IZABRIGHT-Lung01)Bristol Myers Squibb · 661 people · enrolling Dec 2028
- Telisotuzumab adizutecan with osimertinibAbbVie · 490 people · enrolling Sep 2030
Stronger first-line combinations
47.5 months median survivalDetails and 1 trialsHide
Adding chemotherapy or amivantamab up front to delay resistance, and learning who needs the extra side effects.
WatchLonger follow-up and quality-of-life data.
Earlier-stage treatment
26% major pathologic responseDetails and 3 trialsHide
EGFR pills before or after surgery and after chemoradiation, to lower the chance the cancer returns.
WatchADAURA2; REZILIENT4.
Uncommon mutations
35.2% tumors shrankDetails and 3 trialsHide
New pills for exon 20 insertions and PACC mutations, which respond poorly to osimertinib.
WatchFURVENT; REZILIENT3.
Borrowed from other cancers
From Breast cancer
Datopotamab deruxtecan (Dato-DXd)
Phase 3
A TROP2 antibody-drug conjugate first approved for HR-positive breast cancer; now approved for previously treated EGFR-mutated lung cancer and in first-line trials.
From Breast cancer
Sacituzumab tirumotecan
Phase 3
A TROP2 antibody-drug conjugate also being tested in triple-negative and HR-positive breast cancer.
From Other lung cancers
Ivonescimab
Phase 3
A PD-1 and VEGF bispecific antibody tested across non-small cell lung cancer.
Open to join now
-
Advanced disease, first treatment
Osimertinib with or without Dato-DXd
Locations and eligibility → -
After EGFR pills stopped working
Iza-bren
Locations and eligibility → -
Advanced EGFR-mutated disease
Telisotuzumab adizutecan
Locations and eligibility → -
Early-stage, uncommon mutations
Zipalertinib after surgery
Locations and eligibility → -
PACC uncommon mutations, first treatment
Firmonertinib
Locations and eligibility →
See every recruiting EGFR lung cancer trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
HER3 antibody-drug conjugate beats chemotherapy after EGFR pills
HERON-Lung01, The Lancet.
Ivonescimab delays progression; survival gain not significant globally
HARMONi, Lancet Oncology.
Osimertinib plus chemo extends survival
FLAURA2, NEJM.
Sac-TMT extends survival after resistance
OptiTROP-Lung04, NEJM.
Standard treatment today
- Early stage, after surgeryOsimertinib for 3 years after surgery (stage IB to IIIA), with chemotherapy when advised.
- Stage III, not operableChemotherapy and radiation, then osimertinib.
- Advanced, first treatmentOsimertinib alone, osimertinib plus chemotherapy, or amivantamab plus lazertinib.
- After osimertinib stops workingA new biopsy to look for resistance changes (such as MET), then amivantamab plus chemotherapy, chemotherapy, or Dato-DXd.
- Exon 20 insertionsAmivantamab plus chemotherapy first; sunvozertinib later.
How to read this page, and sourcesHow to read this page, and sources
- Several of the newest results come from trials run only in China; global trials are checking whether they hold elsewhere.
- This page covers EGFR-mutated non-small cell lung cancer. Other lung cancers have different treatments.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See EGFR lung cancer trials recruiting now →